HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) A corrigendum has been published Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (18) Citing Articles via Google Scholar Google Scholar Articles by Grover, G. J. Articles by Green, D. W. Search for Related Content PubMed PubMed Citation Articles by Grover, G. J. Articles by Green, D. W.

Excessive ATP hydrolysis in ischemic myocardium by mitochondrial F₁F₀-ATPase: effect of selective pharmacological inhibition of mitochondrial ATPase hydrolase activity

Metabolic and Cardiovascular Drug Discovery, Bristol-Myers-Squibb Pharmaceutical Research Institute, Pennington, New Jersey 08534

Submitted 15 December 2003 ; accepted in final form 26 May 2004

Mitochondrial F₁F₀-ATPase normally synthesizes ATP in the heart, but under ischemic conditions this enzyme paradoxically causes ATP hydrolysis. Nonselective inhibitors of this enzyme (aurovertin, oligomycin) inhibit ATP synthesis in normal tissue but also inhibit ATP hydrolysis in ischemic myocardium. We characterized the profile of aurovertin and oligomycin in ischemic and nonischemic rat myocardium and compared this with the profile of BMS-199264, which only inhibits F₁F₀-ATP hydrolase activity. In isolated rat hearts, aurovertin (1–10 µM) and oligomycin (10 µM), at concentrations inhibiting ATPase activity, reduced ATP concentration and contractile function in the nonischemic heart but significantly reduced the rate of ATP depletion during ischemia. They also inhibited recovery of reperfusion ATP and contractile function, consistent with nonselective F₁F₀-ATPase inhibitory activity, which suggests that upon reperfusion, the hydrolase activity switches back to ATP synthesis. BMS-199264 inhibits F₁F₀ hydrolase activity in submitochondrial particles with no effect on ATP synthase activity. BMS-199264 (1–10 µM) conserved ATP in rat hearts during ischemia while having no effect on preischemic contractile function or ATP concentration. Reperfusion ATP levels were replenished faster and necrosis was reduced by BMS-199264. ATP hydrolase activity ex vivo was selectively inhibited by BMS-199264. Therefore, excessive ATP hydrolysis by F₁F₀-ATPase contributes to the decline in cardiac energy reserve during ischemia and selective inhibition of ATP hydrolase activity can protect ischemic myocardium.

ischemia; heart; reperfusion

This article has been cited by other articles:

				S. Hong and P. L. Pedersen ATP Synthase and the Actions of Inhibitors Utilized To Study Its Roles in Human Health, Disease, and Other Scientific Areas Microbiol. Mol. Biol. Rev., December 1, 2008; 72(4): 590 - 641. [Abstract] [Full Text] [PDF]

				E. Murphy and C. Steenbergen Mechanisms Underlying Acute Protection From Cardiac Ischemia-Reperfusion Injury Physiol Rev, April 1, 2008; 88(2): 581 - 609. [Abstract] [Full Text] [PDF]

				P. Wang, C. Zaragoza, and W. Holman Sodium-Hydrogen Exchange Inhibition and {beta}-Blockade Additively Decrease Infarct Size Ann. Thorac. Surg., March 1, 2007; 83(3): 1121 - 1127. [Abstract] [Full Text] [PDF]

				M. Comelli, G. Metelli, and I. Mavelli Downmodulation of mitochondrial F0F1 ATP synthase by diazoxide in cardiac myoblasts: a dual effect of the drug Am J Physiol Heart Circ Physiol, February 1, 2007; 292(2): H820 - H829. [Abstract] [Full Text] [PDF]